Approaches to Improving Cardiac Structure and Function During and After an Acute Myocardial Infarction: Acute and

Robert A Kloner1, Wangde Dai2, Sharon L Hale3

  • 1HMRI Cardiovascular Research Institute, Huntington Medical Research Institutes, Pasadena, California, USA Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA Guest Editor: Jonathan Leor kloner@hmri.org.

Insights

Myocardial infarction (MI) remains a significant health issue. New therapies are needed to reduce heart damage during ischemia and improve cardiac structure and function post-MI.

Area of Science:

  • Cardiology
  • Regenerative Medicine

Background:

  • Myocardial infarction (MI) continues to cause significant mortality and morbidity despite advancements in reperfusion therapy.
  • Current strategies targeting reperfusion injury have shown limited clinical success in acute ST-segment elevation myocardial infarction.
  • Reducing myocardial cell death during ischemia is crucial for limiting infarct size.

Purpose of the Study:

  • To explore therapeutic strategies for reducing myocardial infarct size.
  • To investigate methods for mitigating adverse left ventricular remodeling post-MI.
  • To identify optimal approaches for preserving cardiac structure and function after infarction.

Main Methods:

  • Review of current therapeutic approaches for myocardial infarction.
  • Discussion of strategies targeting ischemic cell death.
  • Exploration of regenerative cardiology principles, including cellular and non-cellular therapies.
  • Consideration of pharmacologic agents for chronic administration.

Main Results:

  • Therapies reducing cell death during ischemia show promise for limiting infarct size.
  • Regenerative approaches, including extracellular matrix, may aid in reducing left ventricular remodeling.
  • A dual therapeutic approach targeting both acute infarct size reduction and chronic remodeling is proposed.

Conclusions:

  • Reducing myocardial cell death during ischemia is a key strategy to limit infarct size.
  • Therapies promoting favorable left ventricular remodeling are essential for long-term cardiac function.
  • A combined approach, addressing both acute injury and chronic healing, offers the most effective means to preserve cardiac structure and function after myocardial infarction.

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
446
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
634
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
697
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
751
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
319